JP2014513951A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513951A5
JP2014513951A5 JP2014506553A JP2014506553A JP2014513951A5 JP 2014513951 A5 JP2014513951 A5 JP 2014513951A5 JP 2014506553 A JP2014506553 A JP 2014506553A JP 2014506553 A JP2014506553 A JP 2014506553A JP 2014513951 A5 JP2014513951 A5 JP 2014513951A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
acid sequence
amino acid
endoglin polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014506553A
Other languages
English (en)
Japanese (ja)
Other versions
JP6250533B2 (ja
JP2014513951A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/034295 external-priority patent/WO2012145539A1/en
Publication of JP2014513951A publication Critical patent/JP2014513951A/ja
Publication of JP2014513951A5 publication Critical patent/JP2014513951A5/ja
Application granted granted Critical
Publication of JP6250533B2 publication Critical patent/JP6250533B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014506553A 2011-04-20 2012-04-19 エンドグリンポリペプチドおよびその使用 Expired - Fee Related JP6250533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477585P 2011-04-20 2011-04-20
US61/477,585 2011-04-20
PCT/US2012/034295 WO2012145539A1 (en) 2011-04-20 2012-04-19 Endoglin polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017224413A Division JP6803315B2 (ja) 2011-04-20 2017-11-22 エンドグリンポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2014513951A JP2014513951A (ja) 2014-06-19
JP2014513951A5 true JP2014513951A5 (enExample) 2015-06-18
JP6250533B2 JP6250533B2 (ja) 2017-12-20

Family

ID=46000405

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014506553A Expired - Fee Related JP6250533B2 (ja) 2011-04-20 2012-04-19 エンドグリンポリペプチドおよびその使用
JP2017224413A Expired - Fee Related JP6803315B2 (ja) 2011-04-20 2017-11-22 エンドグリンポリペプチドおよびその使用
JP2020134862A Active JP7097930B2 (ja) 2011-04-20 2020-08-07 エンドグリンポリペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017224413A Expired - Fee Related JP6803315B2 (ja) 2011-04-20 2017-11-22 エンドグリンポリペプチドおよびその使用
JP2020134862A Active JP7097930B2 (ja) 2011-04-20 2020-08-07 エンドグリンポリペプチドおよびその使用

Country Status (8)

Country Link
US (3) US9932386B2 (enExample)
EP (2) EP2699590B8 (enExample)
JP (3) JP6250533B2 (enExample)
CN (3) CN103781798B (enExample)
AU (4) AU2012245439B2 (enExample)
CA (1) CA2833747C (enExample)
DK (1) DK2699590T3 (enExample)
WO (1) WO2012145539A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
WO2013019805A1 (en) 2011-08-01 2013-02-07 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
WO2015042269A1 (en) 2013-09-20 2015-03-26 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
EP3060235B1 (en) * 2013-10-25 2020-12-02 Acceleron Pharma Inc. Endoglin peptides to treat fibrotic diseases
WO2015077540A2 (en) * 2013-11-21 2015-05-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
EP3122375B1 (en) 2014-03-28 2021-03-03 University of Washington through its Center for Commercialization Breast and ovarian cancer vaccines
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
WO2016019368A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9884900B2 (en) 2015-08-04 2018-02-06 Acceleron Pharma Inc. Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
CN106674352B (zh) * 2015-11-10 2020-05-15 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物及应用
US20180086806A9 (en) * 2016-04-06 2018-03-29 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
AU2017293778B2 (en) * 2016-07-07 2022-03-24 Acceleron Pharma Inc. TGF-beta superfamily heteromultimers and uses thereof
ES2948647T3 (es) 2017-05-04 2023-09-15 Acceleron Pharma Inc Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
US20210107959A1 (en) * 2018-01-03 2021-04-15 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
WO2020219796A1 (en) * 2019-04-26 2020-10-29 Vanderbilt University Probes for detecting rna and methods of use thereof
WO2021026337A1 (en) * 2019-08-07 2021-02-11 Icahn School Of Medicine At Mount Sinai Method of treating keloids
US20230285506A1 (en) * 2019-12-03 2023-09-14 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
US20220233714A1 (en) * 2021-01-27 2022-07-28 Vanderbilt University Nanogold-dna bioconjugates and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
EP0667870A4 (en) * 1992-10-30 1998-04-01 Hsc Res Dev Lp COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF--g(b).
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
KR100794454B1 (ko) 1997-04-07 2008-01-16 제넨테크, 인크. 항-ｖｅｇｆ 항체
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU7467898A (en) 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
AU3369999A (en) 1998-04-02 1999-10-25 Genentech Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
DK1292335T3 (da) 2000-06-23 2007-09-17 Bayer Schering Pharma Ag Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2004249675B2 (en) 2003-05-22 2010-04-15 Abbvie Bahamas Ltd. Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
KR20150008458A (ko) 2003-05-30 2015-01-22 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US20090170767A1 (en) 2006-05-31 2009-07-02 Beth Israel Deaconess Medical Center Soluble Endoglin Compounds for the Treatment and Prevention of Cancer
MX2009004718A (es) * 2006-11-02 2009-06-19 Acceleron Pharma Inc Antagonistas de receptor de alk1 y ligando y sus usos.
JP2010529041A (ja) * 2007-06-01 2010-08-26 ワイス・エルエルシー Ｂｍｐ−１０活性を調整する方法および組成物
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US20100210713A1 (en) 2009-01-16 2010-08-19 The General Hospital Corporation Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
CN102548617B (zh) * 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途
EP2427494B1 (en) * 2009-05-08 2017-10-18 Novartis AG Methods of modulating fibrosis using bone morphogenetic protein-9 (bmp-9) modulators
US8795663B2 (en) * 2010-01-12 2014-08-05 Beth Israel Deaconess Medical Center, Inc. Soluble endoglin and uses thereof
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
WO2013019805A1 (en) 2011-08-01 2013-02-07 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
WO2015042269A1 (en) 2013-09-20 2015-03-26 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
EP3060235B1 (en) 2013-10-25 2020-12-02 Acceleron Pharma Inc. Endoglin peptides to treat fibrotic diseases
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2014513951A5 (enExample)
JP2013172734A5 (enExample)
JP2011155981A5 (enExample)
JP2013523703A5 (enExample)
IL281648A (en) Solid forms of }[5-(3-chlorophenyl)-3-hydroxypyridi-2-carbonyl]amino{ acetic acid, their compositions and uses
JP2011136997A5 (enExample)
HUE062740T2 (hu) GLP-1 peptidek készítményei és elõállításuk
JP2014132019A5 (enExample)
ZA201308251B (en) Amino acid sequence presenting fusion polypeptide and its use
EP2822923A4 (en) PREPARATION OF ALPHA, BETA-UNSATURATED CARBOXYLIC ACIDS AND THEIR ESTERS
JP2015038108A5 (enExample)
JP2011136981A5 (enExample)
CO7020851A2 (es) Proteínas y péptidos modificados
HUE054444T2 (hu) Prolinnal lezárt kapcsos peptidek és felhasználásuk
JP2012126742A5 (enExample)
JP2014503607A5 (enExample)
IN2015KN00262A (enExample)
UA118167C2 (uk) Пептид та його застосування
IL229539A0 (en) Hyaluronic acid-binding synthetic peptidoglycans, prepartion, and methods of use
BR112013018742A2 (pt) cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática
GB201315335D0 (en) Amino diacids containing peptide modifiers
JP2015533791A5 (enExample)
JP2010265269A5 (enExample)
AP2015008948A0 (en) Modified matrix proteins of vesicular stomatitis virus
PH12016500101A1 (en) Protease-resistant peptide ligands